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INTRODUCTION
Stem cell or solid organ transplantation (SOT) is essential treat-
ments for patients with hematological malignancies or organ fail-
ure. Treatment success can be limited by infectious complications 
caused by common pathogens such as cytomegalovirus (CMV), 
Epstein-Barr virus (EBV), BK virus (BKV) or adenovirus (ADV) that 
arise as a result of profound immunosuppression after transplanta-
tion.1–3 Antiviral drugs given either prophylactically or as early ther-
apy for patients with detectable viral loads are an effective strategy 
for reducing viral infections.4–6 However, long-term treatment with 
these drugs is associated with significant toxicity, expense and the 
appearance of drug-resistant virus isolates, which ultimately results 
in treatment failure.7–9 Cellular immunotherapy has emerged as an 
effective alternative treatment that can prevent or reduce virus-
associated transplant complications while being associated with 
much lower toxicity.10–17 One of the major limitations of autologous 
or donor-derived T-cell therapy is that the process of generating 
these effector cells often takes many weeks or months. This limits 
the use of this approach therapeutically, because the patients often 
succumb to progressive disease or lose their graft before the T-cells 
are ready for infusion. Ideally, a T-cell therapy that can be offered 
as an “off-the-shelf” treatment would be more suitable for these 
patients. A second limitation is that T-cell preparations often only 
target a single pathogen which restricts their utility for patients 
presenting with multiple infections and makes the generation of 
T-cell banks more laborious and costly. While recent studies have 
successfully developed strategies to expand multivirus-specific 
T-cells,18–20 one major limitation in the manufacture of these effector 
cells is that the precise epitope specificity of T-cells expanded using 
a complex mixture of synthetic peptides remains poorly defined. 
Moreover, the use of mixtures of overlapping peptides from mul-
tiple antigens increases the potential risk of expansion of allogeneic 
T-cells which may be reactive against engrafted organ. This is par-
ticularly relevant for SOT patients where the risk of graft rejection 
by allogeneic T-cells is much higher when compared with stem cell 
transplant recipients. To overcome these limitations, we have devel-
oped a novel replication-deficient adenoviral antigen presentation 
system which encodes multiple human leukocyte antigen (HLA) 
class I-restricted minimal T-cell epitopes from EBV, CMV, BKV, and 
ADV as a polyepitope protein (referred to as Ad-MvP). We demon-
strate that the Ad-MvP platform can be used for the rapid expansion 
of multivirus-specific cytotoxic T-cells from SOT recipients following 
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Viral infections including cytomegalovirus, Epstein-Barr virus, adenovirus, and BK virus are a common and predictable problem in 
transplant recipients. While cellular immune therapies have been successfully used to tackle infectious complications in transplant 
recipients, manufacturing immunotherapies to address the multitude of possible pathogens can be technically challenging and 
labor-intensive. Here we describe a novel adenoviral antigen presentation platform (Ad-MvP) as a tool for rapid generation of multi-
virus-specific T-cells in a single step. Ad-MvP encodes 32 CD8+ T-cell epitopes from cytomegalovirus, Epstein-Barr virus, adenovirus, 
and BK virus as a contiguous polyepitope. We demonstrate that Ad-MvP vector can be successfully used for rapid in vitro expansion 
of multivirus-specific T-cells from transplant recipients and in vivo priming of antiviral T-cell immunity. Most importantly, using an in 
vivo murine model of Epstein-Barr virus-induced lymphoma, we also show that adoptive immunotherapy with Ad-MvP expanded 
autologous and allogeneic multivirus-specific T-cells is highly effective in controlling Epstein-Barr virus tumor outgrowth and 
improving overall survival. We propose that Ad-MvP has wide ranging therapeutic applications in greatly facilitating in vivo priming 
of antiviral T-cells, the generation of third-party T-cell banks as “off-the-shelf” therapeutics as well as autologous T-cell therapies for 
transplant patients.
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single stimulation and that these T-cells are highly effective in con-
trolling virus-associated B cell lymphoma. In addition, Ad-MvP can 
also be used successfully for priming and/or boosting multivirus-
specific T-cells in vivo. Use of the Ad-MvP vector will greatly facili-
tate the rapid production of multivirus-specific T-cell banks to make 
autologous or “off-the-shelf” T-cell therapy readily available for 
transplant patients.
ReSUlTS
Single stimulation with Ad-MvP is sufficient to expand polyfunctional 
multivirus specific T-cells from transplant recipients
In the first set of experiments, we explored the potential application 
of the Ad-MvP antigen presentation system for transplant recipients. 
We recruited a cohort of SOT recipients who had either ongoing 
Table 1 Clinical characteristics of SOT recipients
Patient ID Age/sex Organ Drugs Serological status
Antiviral  
treatment
CMV/EBV/BKV  
reactivations post tx
CMV/EBV/BKV 
disease
SOT02 lung FK, MMF, P R+/D+ (CMV) Val 2 (CMV) Yes (eye)
SOT06 lung CsA, MMF, P R+/D+ (CMV) Gan, Val 2 (CMV) Yes (lung)
SOT26 lung FK, MMF, P R+/D+ (CMV) Val 2 (CMV) No
SOT35 lung CsA, MMF, P, FK R−/D+ (CMV) Val 1 (CMV) No
SOT56 kidney TK, MMF, P R+/D− (CMV) Val 0 No
SOT58 kidney FK, MMF, P,B R−/D+ (CMV) Gan 1 (CMV) No
SOT62 kidney CsA, MMF, P, FK R+/D− (CMV) None 3 (CMV) No
SOT68 kidney CsA, MMF, P R−/D+ (CMV) Val 2 (CMV) No
SOT75 kidney CsA, MMF, P, FK R−/D+ (CMV) Gan, Val 3 (CMV) No
SOT22 Lung CsA, P, MMF, AZA R−/D+ (EBV) Gan 2 (EBV) Yes (PTLD)
SOT33 Heart CsA, P AZA R−/D+ (EBV) Val 2 (EBV) Yes (PTLD)
SOT59 Lung CsA, AZA, P R−/D+ (EBV) NA 1 (EBV) Yes (PTLD)
SOT15 Kidney FK, P, E R−/D+ (BKV) None 1 (BKV) Yes (BKVAN)
SOT22 Kidney FK, P R−/D+ (BKV) Lef 1 (BKV) Yes (BKVAN)
ADV, adenovirus; AZA, azathioprine; B , basiliximab; BKV, BK virus; BKVAN, BK-associated nephropathy; CMV, cytomegalovirus; CsA, cyclosporin A; D, donor; 
EBV, Epstein-Barr virus; E, Everolimus; FK, tacrolimus; Gan, ganciclovir; Lef, Leflunomide; MMF, mycophenolate mofetil; P, prednisone; PTLD, post-transplant 
lymphoproliferative disorder; R, recipient; SOT, solid organ transplantation; tx, transplantation; Val, valganciclovir , , . 
Figure 1  Schematic outline for the construction of Ad-MvP Synthetic DNA sequence encoding a polyepitope protein containing contiguous 32 HLA 
class I-restricted CTL epitopes from BKV (red text), ADV (violet text), CMV (blue text), and EBV (green text) was cloned into a pShuttle vector and then 
subcloned into the Ad5F35 expression vector. The recombinant Ad5F35 vector was packaged into infectious adenovirus by transfecting HEK 293 cells, 
and recombinant adenovirus (referred to as Ad-MvP) was harvested from transfected cells by repeated freeze-thawing cycles. ADV, adenovirus; BKV, 
BK virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus.
5′ Nhe I MLTERFNHI LLLLIWFRPV SITEVECFL LPLMRKAYL RLDSEISMY SVKVNLEKK AYLRKCKEF
TDLGQNLLY TYFSLNNKF MPNRPNYIAF GLRYRSMLL LPGSYTYEW IPYLDGTFY VLAWTRAFV FLGRQLPKL
VTEHDTLLY YSEHPTFTSQY NLVPMVATV FPTKDVAL QYDPVAALF AYAQKIFKIL RPHERNGFTVL ELRRKMMYM
IPSINVHHY TRATKMQVI TTVYPPSSTAK GPISHGHVLK HERNGFTVL CLGGLLTMV GLCTLVAML SSCSSCPLSKI
TYGPVFMCL RPPIFIRRL FLRGRAYGL RAKFKQLL HPVGEADYFEY YPLHEQHGM VEITPYKPTW Kpn I 3′
Nhe I Kpn I
pShuttle
I-Ceu I
I-Ceu I
PI-Sce I
PI-Sce I
multipathogen polyepitope
pAd5F35
I-Ceu I PI-Sce I
Pac IPac I Pac I digestion (to linearize) Transfection of HEK 293 cells
Collection of recombinant adenovirus
Ad-MvP
3Preclinical assessment of multivirus immunotherapy
V Dasari et al.
Molecular Therapy — Methods & Clinical Development (2016) 16058Official journal of the American Society of Gene & Cell Therapy
or a previous history of recurrent viral reactivation/disease (CMV, 
EBV or BKV; Table 1). Peripheral blood mononuclear cells (PBMC) 
from these SOT recipients were stimulated with Ad-MvP (Figure 1) 
at a multiplicity of infection at 10:1 and then cultured for 14 days. 
Representative data from two different transplant recipients pre-
sented in Figure 2a shows that a single stimulation with Ad-MvP was 
sufficient to induce the rapid expansion of T-cells specific for ADV, 
BKV, CMV, and EBV epitopes. T-cells expanded from SOT33 showed 
strong reactivity toward CMV and EBV, while T-cells expanded from 
SOT15 showed strong reactivity against CMV but also EBV, BKV, and 
ADV. A comprehensive summary of T-cell expansions following 
Ad-MvP stimulation from 14 SOT recipients is presented in Figure 
2b. These analyses showed that CMV, BKV, EBV, and ADV-specific 
T-cell expansions were observed in 86, 71, 86, and 29% of SOT 
patients respectively (Figure 2b). More importantly, the majority 
of these in vitro expanded T-cells showed a polyfunctional profile 
(Figure 2c). Taken together, these studies showed that Ad-MvP is 
highly efficient in expanding multivirus-specific T-cells from trans-
plant recipients and this expansion is not impacted by underlying 
immunosuppression or ongoing viral reactivation/disease.
In vivo priming of multivirus-specific T-cells with Ad-MvP
In addition to the potential application of Ad-MvP as a tool for in vitro 
expansion of pre-existing memory/effector T-cells, using a mouse 
model we also explored the utility of this vector for in vivo priming 
of multivirus-specific T-cells in seronegative transplant recipients/
donors. Transgenic mice expressing the HLA A*0201 allele (referred to 
as HHD II mice) were immunized with Ad-MvP (0.5 × 108 pfu/mouse) 
and then one group was boosted with the same dose on day 21. On 
day 50 postimmunization, these mice were assessed for antigen-
specific T-cell responses. While ex vivo analysis revealed strong T-cell 
response to EBV epitopes and a low or undetectable response toward 
epitopes from CMV, BKV, and ADV, a 6–240 fold increase in antigen-
specific T-cells was observed following in vitro stimulation with BKV, 
ADV, CMV, or EBV-specific HLA-A*0201-restricted peptide pools 
(Figure 3a). A comprehensive summary of multiple HLA-A2-restricted 
T-cell responses in HHD II mice following Ad-MvP prime alone and 
prime-boost immunization is shown in Figure 3b. This analysis also 
showed that while in both the prime alone and prime-boost setting 
EBV-specific T-cell responses were the dominant component of ex vivo 
analysis, a significant change in the composition of antigen-specific 
T-cells was observed following in vitro stimulation. Taken together, 
these experiments clearly demonstrated that Ad-MvP vector is highly 
efficient in inducing multivirus-specific T-cells in vivo.
Expansion of multivirus-specific T-cells from healthy donors with 
Ad-MvP for third-party T-cell bank
While autologous T-cell therapy has been successfully used to 
treat many SOT recipients, many patients are not amenable to this 
therapy due to severe lymphopenia or transplant-related clinical 
Figure 2 Expansion of multivirus-specific T-cells from solid-organ transplant recipients with Ad-MvP. PBMC from 14 SOT patients were stimulated 
with Ad-MvP and cultured for 14 days in the presence of IL-2. The frequency of epitope specific CTL was determined by measuring IFNγ production in 
response to stimulation with virus-specific peptide pools containing epitopes encoded in Ad-MvP. (a) Representative dot plots following recall with 
CMV, EBV, BKV or ADV peptide epitopes is shown. (b) Data represents a summary of the number of virus-specific IFNγ-producing CD8+ T-cells from 
all SOT patients. Black symbols represent patients recruited with CMV-associated complications, red symbols represent patients with EBV-associated 
PTLD, and blue symbols represent patients with BKV viremia (c) Ad-MvP expanded CTL were assessed for the intracellular production of IFNγ, TNF, 
IL-2, and externalization of CD107a following in vitro stimulation with the virus-specific peptide pools. Boolean Analysis was performed using FlowJo 
Software (Ashland, OR). Pie Charts represent the proportion of T-cells specific for each virus capable of generating monofunctional and polyfunctional 
CD8+ T-cells that produce various combinations of IFNγ, TNF, IL-2, and externalisation of CD107a simultaneously. ADV, adenovirus; BKV, BK virus; CMV, 
cytomegalovirus; EBV, Epstein-Barr virus; IFNγ, interferon gamma; IL-2, interleukin-2; PBMC, peripheral blood mononuclear cells; SOT, solid organ 
transplantation; TNF, tumor necrosis factor.
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complications. More recently, third-party HLA matched virus-spe-
cific T-cell therapy has emerged as an excellent alternative to autol-
ogous cellular therapy. To assess Ad-MvP as a potential tool for man-
ufacturing T-cell banks, PBMCs from a panel of healthy volunteers 
were stimulated with autologous PBMCs infected with Ad-MvP at 
a multiplicity of infection of 10:1 and then cultured for 14 days. Ex 
vivo analyses showed that the mean T-cell response specific for EBV, 
CMV, BKV, and ADV were 0.33% (range 0–1.12%), 0.49% (0–1.519%), 
0.03% (range 0–0.013%), and 0.006% (range 0–0.054%) respectively. 
A comprehensive summary of T-cell expansions following Ad-MvP 
stimulation from 20 healthy donors is presented in Figure 4a. These 
analyses showed that in all healthy donor samples T-cells specific for 
at least three different viruses were detected. The mean expansions 
of CD8+IFNγ+ T-cells specific for CMV, EBV, BKV, and ADV were 33.83, 
15.91, 1.70, and 1.12% respectively. The polyfunctional profiling of 
these in vitro expanded effector cells showed that 60–80% of EBV, 
CMV, BKV, and ADV-specific T-cells expressed IFNγ, TNF, and/or IL-2 
with strong cytotoxic potential as assessed by CD107a mobilization 
(Figure 4b).
To further refine the culture conditions required for optimal yield 
of multivirus- specific T-cells, we assessed T-cell expansion poten-
tial in the presence of different cytokine combinations in compari-
son to the standard supplementation with IL-2 alone. PBMCs from 
healthy donors were stimulated with Ad-MvP and expanded in 
the presence of combinations of IL-2, IL-21, IL-7, and/or IL-15/IL-7. 
While the overall T-cell expansions and polyfunctional profile was 
slightly improved when cells were cultured in the presence of IL-2 
in combination with IL-21 and IL-15, there was no statistically sig-
nificant difference when compared with T-cell expansion in IL-2 
alone (Figure 4c,d). Similarly, no statistical difference was observed 
in absolute percentage of CD3+/CD4+/CD8+ T-cells following healthy 
donor PBMC stimulation with Ad-MvP and expansion in the pres-
ence of combinations of IL-2, IL-21, IL-7, and/or IL-15/IL-7, however, 
there was a modest increase in the multivirus-specific CD8+ T-cell 
percentage when expanded in the presence of IL-2, IL-7, and IL-15 
or IL-2 and IL-21 cytokine combinations (Figure 5).
Autologous and allogeneic adoptive immunotherapy with Ad-
MvP-expanded T-cells
Having established the in vitro and in vivo immunogenicity of the 
Ad-MvP vector, the next set of experiments were designed to 
assess the potential therapeutic application of the Ad-MvP vector 
in a mouse model of EBV-associated lymphoma. A group of non-
obese diabetic/severe combined immunodeficient (NOD/SCID) 
mice were engrafted with EBV-transformed lymphoblastoid cells 
(Donor code: D01; HLA A1, A11, B8, and B35). Autologous T-cells 
from D01 were expanded using Ad-MvP and which included CD8+ 
T-cells specific for three EBV epitopes (HLA B8 and B35-restricted) 
as well as CMV and ADV (Figure 6a). On day 6 after EBV lymphoma 
induction, mice were adoptively treated with a single injection of 
autologous Ad-MvP expanded T-cells. Data presented in Figure 
Figure 3 Priming of multivirus-specific T-cells following immunization with Ad-MvP. (a) Representative data showing ex vivo and in vitro expanded virus-
specific T-cells from HHD II transgenic mouse immunized with Ad-MvP. (b) Stacked bar graph showing percentage of multivirus-specific CD8+ T-cells 
expressing IFNγ in HLA*A02 transgenic mice immunized with Ad-MvP. Splenocytes from immunized mice were isolated on day 50 postvaccination and 
stimulated in vitro with HLA-A*02-restricted CD8+ T-cell peptide epitopes from BKV, ADV, CMV or EBV. T-cell specificity was assessed using an intracellular 
cytokine assay. ADV, adenovirus; BKV, BK virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus.
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6b,c shows that following adoptive immunotherapy, a significant 
delay in lymphoma outgrowth was observed in mice treated with 
Ad-MvP-expanded autologous T-cells when compared with mock-
treated mice (P = 0.033). Considering the broader applicability of 
allogeneic antigen-specific T-cell therapy, we also assessed the ther-
apeutic efficacy of Ad-MvP expanded T-cells from a HLA-matched 
donor (Donor code: D055; HLA A1, A2, B8, and B40). The expanded 
T-cells from D055 included T-cells specific for CMV, ADV, and four 
EBV epitopes restricted through HLA B8 and HLA A2. T-cells spe-
cific for HLA B8-restricted epitopes (FLR and RAK) matched to the 
EBV lymphoma in NOD/SCID mice (Figure 6d). Tumor bearing mice 
treated with allogeneic multivirus-specific T-cells also showed sig-
nificantly delayed tumor growth (Figure 6e,f; P = 0.0065).
DISCUSSION
T-cell therapy has emerged as an effective treatment tool for viral 
morbidity and mortality after transplant that provides an alterna-
tive to costly prophylactic/pre-emptive antiviral therapy which is 
often limited by toxicity and resistance.10,12,18,21–24 However, trans-
plant patients are often vulnerable to multiple infections and one 
challenge for the broader application of T-cell therapy is the num-
ber of pathogens that can be targeted.25–28 We describe here a novel 
antigen presenting platform designed to stimulate T-cell responses 
to four common pathogens (CMV, EBV, BKV, and ADV) which have 
been identified as the major causes of viral complications after 
transplant. The Ad-MvP platform encodes multiple CD8+ T-cell epi-
topes from the four different viruses as a polyepitope protein. We 
demonstrate that stimulation with Ad-MvP consistently achieved 
twofold to 10-fold expansions of multivirus-specific T-cells both 
from healthy volunteers as well as transplant patients who have 
been heavily pretreated with immunosuppressants and have ongo-
ing EBV or CMV-associated clinical complications. Furthermore, 
we show that both autologous and allogeneic Ad-MvP T-cells can 
control the growth of EBV-associated lymphoma in a xenogeneic 
Figure 4 Expansion of multivirus-specific T-cells using Ad-MvP in healthy volunteers. PBMC from healthy volunteers were stimulated with Ad-MvP 
and expanded in the presence of IL-2 for 14 days. The frequency of epitope specific CTL was determined by measuring IFNγ production in response to 
stimulation with HLA-matched epitopes contained in Ad-MvP. (a) Summary of the frequency of multivirus specific T-cells in a cohort of healthy donors. 
(b) Ad-MvP expanded CTL were stimulated with peptide pools corresponding to the epitopes contained in the polyepitope for each virus. Production 
of IFNγ, TNF, IL-2, and externalization of CD107a were measured as markers of polyfunctionality. (c) In vitro expansion of multivirus-specific CD8+ T-cells 
from healthy donors using Ad-MvP in the presence of different cytokine combinations. (d) The frequency of antigen-specific T-cells following in vitro 
culture in the presence of different cytokines was assessed using intracellular cytokine assays. IFNγ, interferon gamma; IL-2, interleukin-2; PBMC, 
peripheral blood mononuclear cells; TNF, tumor necrosis factor.
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mouse model, demonstrating the potential application of the MvP 
vector for use in both an autologous or HLA-matched allogeneic 
setting.
Recent studies from a number of groups have begun to explore the 
potential application of multivirus-specific T-cells for the treatment 
of a range of viral diseases in transplant patients.16,17,29 The initial pro-
tocols established to generate multivirus-specific T-cells were very 
laborious and dependent upon the production of EBV-transformed 
lymphoblastoid cells as a source of antigen presenting cells (APCs) 
for repeated antigenic stimulation. More recent protocols have 
refined these approaches and now typically employ a single stimula-
tion with pools of overlapping peptide libraries from immunodomi-
nant viral antigens. These multivirus-specific T-cells expanded with 
peptide libraries were recently used in stem cell transplant patients 
and provided a 94% virological and clinical response rate.30 While 
this approach has accelerated the production of multivirus-specific 
T-cells, precise characterization of epitope specificity of these T-cell 
populations may remain a challenge due to the complexity of the 
antigenic stimuli used. In contrast, the Ad-MvP vector simplifies the 
characterization of the clinical product by using a polyepitope of fully 
defined HLA-restricted peptide epitopes. In addition, the Ad-MvP 
approach also provides a platform for the selection of immunodomi-
nant T-cell epitopes irrespective of the antigen source. This is of par-
ticular importance for large viruses, including EBV and CMV, which 
encode between 160–250 open reading frames. Overlapping pep-
tide based approaches targeting single immunodominant antigens, 
such as CMV-pp65, have the potential to exclude immunodominant 
T-cell responses encoded by other antigens.
The capacity to fully characterize T-cell specificity and HLA-
restriction is likely to be of particular importance in the applica-
tion of immunotherapy using allogeneic T-cell banks. This is par-
ticularly relevant for advanced stage development and formal 
Figure 6 Adoptive immunotherapy for EBV-associated B-cell lymphoma using Ad-MvP expanded autologous or allogeneic multivirus-specific T-cells. 
(a, d) Epitope-specificity analysis of Ad-MvP expanded T-cells from donors D01 (HLA A1, A11, B8, B35) and D055 (HLA A1, A2, B8, B40) using intracellular 
cytokine assays (b) NOD/SCID mice (n = 10) were engrafted with EBV transformed lymphoblastoid cells (LCLs) from donor H002 to induce B cell 
lymphoma. On day 6 after engraftment, mice were either mock treated (n = 5) or adoptively infused with autologous 2 × 107 Ad-MvP expanded CTL 
(n = 5; shown in panel a). Tumor volume was measured using vernier calipers. (c) Kaplan-Meier survival graph of EBV tumor bearing mice after mock 
treatment or autologous T-cell therapy. (e) NOD/SCID mice (n = 10) were engrafted with EBV transformed LCL from donor H002 to induce B-cell 
lymphoma. On day 6 after engraftment, mice were either mock treated (n = 5) or adoptively infused with HLA matched allogeneic Ad-MvP expanded 
T-cells from donor H005 (n = 5; shown in panel b). Tumor volume was measured using vernier calipers. Each data points in panels b and e shows mean ± 
SEM of tumor size as measured in multiple mice using vernier calipers. (f) Kaplan–Meier survival graph of EBV tumor bearing mice after mock treatment 
or allogeneic T-cell therapy. EBV, Epstein-Barr virus; LCL, lymphoblastoid cells.
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implementation of these therapies in clinical settings. Allogeneic 
antigen-specific T-cell therapy, which is reliant upon the use of 
healthy seropositive blood donors to generate “off-the shelf” T-cell 
products, has been successfully employed in a number of clinical 
centers using both single and multivirus-specific T-cells.18,19 Using 
a xenogeneic EBV lymphoma model we demonstrated that alloge-
neic T-cells displayed a similar level of protection against tumor bur-
den as that afforded by autologous T-cells. This was in spite of the 
fact that the allogeneic MvP-specific T-cell product matched only 
50% of HLA class I alleles expressed by lymphoma cells.
Another potential application of the Ad-MvP is its use to prime 
virus-specific T-cell responses in seronegative transplant recipients 
prior to transplant. It has been suggested that vaccination of sero-
negative patients before transplant could provide protection against 
common infectious complications post-transplant.31–34 While a sig-
nificant amount of preclinical and clinical research has been under-
taken to explore the use of vaccination in transplant patients, par-
ticularly in the context of CMV, the capacity to induce T-cell memory 
against multiple potential infectious complications using a single 
vaccine vector has the potential to reduce the cost associated with 
developing a vaccine platform for each disease. Using a HLA trans-
genic mouse model, we demonstrated that Ad-MvP induced robust 
responses to multiple viruses that could be recalled and expanded 
following restimulation with viral peptide epitopes. These observa-
tions provide preclinical evidence that in addition to its potential use 
a platform to rapidly generate multivirus-specific T-cells, the Ad-MvP 
vector also has potential use as a vaccine vehicle to induce memory 
T-cell immunity against multiple viruses in a single dose.
Adoptive immunotherapy with either autologous or allogeneic 
HLA matched multivirus-specific T-cells has the potential to provide 
a simplified platform for the treatment of multiple infectious com-
plications associated with organ transplantation. For this approach 
to be broadly applicable several criteria must be fulfilled including 
simple and rapid manufacturing protocols, broad HLA-coverage, 
targeting of multiple viral epitopes and effectiveness against more 
than one common pathogen. We have demonstrated that the 
Ad-MvP vector addresses all of the above criteria, and is therefore 
likely to be a valuable tool to make T-cell therapy readily available to 
treat viral complications after transplantation.
MATeRIAlS AND MeTHODS
Construction of multivirus adenoviral vector (Ad-MvP)
The amino acid sequence of the 32 contiguous HLA class-I restricted CD8+ 
T-cell epitopes as a polyepitope from CMV, EBV, ADV, and BKV (Table 2) 
was translated into the nucleotide sequence using human universal codon 
usage. These epitopes have been previously described.35–38 The nucleotide 
acid sequence encoding the polyepitope with Nhe I and Kpn I restriction 
sites at 5′ and 3′ respectively was cloned into the pShuttle expression vec-
tor. Following amplification, the expression cassette from pShuttle was sub-
cloned into an Ad5F35 expression vector. The recombinant Ad5F35 vector 
was transfected into human embryonic kidney HEK293 cells, and recombi-
nant adenovirus (referred to as Ad-MvP) stocks were produced in HEK293 
cells (Figure 1).
In vitro expansion of multivirus-specific T-cells
PBMCs were isolated from peripheral blood by Ficoll gradient, washed and 
resuspended in Roswell Park Memorial Institute (RPMI)-1640 supplemented 
with 10% foetal bovine serum (FBS) (growth medium) or revived from frozen 
stocks and rested for at least 1 hour at 37°C before being used in T-cell assays. 
The cells were divided into responder and stimulator cells at a responder to 
stimulator ratio of 2:1. The stimulator cells were infected with Ad-MvP at a 
multiplicity of infection of 10:1 for 1 hour at 37°C. Unbound virus particles 
were washed off and the stimulator cells were cocultured with the responder 
cells in the presence of different cytokines as indicated (interleukin-2, IL-2 = 
Table 2 List of HLA class I restricted T-cell epitopes included 
in Ad-MvP
Virus Sequencea Antigen HLA restriction
BKV MlTeRFNHIl large T antigen A*02
lllIWFRPV large T antigen A*02:01
SITeVeCFl VP1 A*02:01
lPlMRKAYl large T antigen B*07:02, B*08
RlDSeISMY large T antigen A*01
SVKVNleKK large T antigen A*03
AYlRKCKeF large T antigen A*24
ADV TDLGQNLLY hexon protein A*01
TYFSLNNKF hexon protein A*24:02
MPNRPNYIAF hexon protein B*07, B*35
GLRYRSMLL hexon protein A*02:02
LPGSYTYEW hexon protein B*53:01
IPYLDGTFY hexon protein B*35, B*53:01
VlAWTRAFV DNA polymerase A*02
FlGRQlPKl DNA binding 
protein
A*02
CMV VTeHDTllY pp50 A*01
YSeHPTFTSQYb pp65 A*01, B*44
NlVPMVATV pp65 A*02:01
FPTKDVAl pp65 B*35:02, B*35:08
QYDPVAAlF pp65 A*24:02
AYAQKIFKIl IE-1 A*23:01, A*24:02
RPHeRNGFTVl pp65 B*07:02
elRRKMMYM IE-1 B*08:01
IPSINVHHY pp65 B*35:01
TRATKMQVI pp65 C*06:02
TTVYPPSSTAK pp150 A*03:01, A*68:01
GPISHGHVlK pp65 A*11
HeRNGFTVl pp65 B*40:01
eBV ClGGllTMV LMP2a A*02:01
GlCTlVAMl BMLF1 A*02:01
SSCSSCPlSKI LMP2a A*11:01
TYGPVFMCl LMP2a A*24:02
RPPIFIRRl EBNA3A B*07:02
FlRGRAYGl EBNA3A B*08:01
RAKFKQll BZLF1 B*08:01
HPVGeADYFeYb EBNA1 B*35:01, 
B*35:08, B*53:01
YPlHeQHGM EBNA3A B*35:01, 
B*35:02, B*35:03
VeITPYKPTW EBNA3B B*44:02
ADV, adenovirus; BKV, BK virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus. 
aBold epitopes are included in the polyepitope, nonbold epitopes are delivered 
by the adenoviral vector. bUnderlined sequences indicate epitopes that are 
embedded in the larger sequence and their respective HLA restrictions.
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120 IU/ml, IL-21 = 30 ng/ml, IL-7 = 10 ng/ml, and/or IL-15 = 10 ng/ml). Every 
3–4 days, the cultures were supplemented with growth medium containing 
the respective cytokines. Virus-specific T-cell expansion was tested on day 14 
using an intracellular cytokine assay.
Characterization of multivirus specific CTL by intracellular cytokine 
assay and flow cytometry
PBMCs or cultured T-cells were stimulated with 1 μg/ml peptides correspond-
ing to defined HLA class I-restricted CD8+ T-cell epitopes derived from CMV, 
EBV, BKV or ADV proteins and incubated in the presence of a CD107a-antibody, 
Brefeldin A and Monensin for 5 hours. After surface staining for CD8 and CD4, 
cells were fixed and permeabilized with cytofix/cytoperm and stained for IFNγ, 
IL-2, and TNF. Stained cells were resuspended in phosphate-buffered saline 
containing 2% paraformaldehyde and acquired using a FACSCanto II or LSR 
Fortessa with FACSDiva software (BD Biosciences,San Jose, CA). Postacquisition 
analysis was conducted using FlowJo software (version 10.1r7).
Ad-MvP immunization in HLA transgenic mice
All animal immunization protocols were conducted in compliance with the 
QIMR Berghofer Medical Research Institute Animal Ethics Committee. HLA-
A*02 transgenic mice (HHD II) were maintained in a pathogen–free animal 
facility at QIMR Berghofer. Three groups (placebo, prime, and prime-boost) 
of 6–8 week old female mice were injected intramuscularly with 50 μl phos-
phate-buffered saline or 50 μl Ad-MvP (1 × 109 pfu/ml). A booster dose was 
given on day 21 to the prime-boost group. Mice were sacrificed on day 50, 
splenocytes from all the groups were stimulated in vitro with BKV, ADV, CMV 
or EBV-specific HLA-A*02 restricted peptide pools. Splenocytes were cul-
tured in a 24-well plate for 10 days at 37°C, 10% CO2. On days 3 and 6, cultures 
were supplemented with growth medium containing recombinant IL-2. 
T-cell specificity was assessed using an intracellular cytokine staining assay.
Adoptive transfer of multivirus specific T-cells in an EBV lymphoma 
model
Two groups of adult (6–10 week-old) NOD/SCID mice irradiated with a 
single dose of 230 cGy were engrafted subcutaneously with 107 EBV-
transformed lymphoblastoid cells per mouse. Tumor growth was moni-
tored every 2−3 days using vernier calipers. Six days after engraftment 
of lymphoblastoid cells, mice were either mock treated or infused with 
2 × 107 Ad-MvP-expanded T-cells. These in vitro-expanded T-cells included 
EBV-, CMV-, ADV-, and BKV-specific T-cells. Tumor burden was monitored 
after adoptive T-cell therapy and mice were sacrificed when tumor volume 
reached 1,000 m3.
Statistical analysis
The group difference between mice treated with Ad-MvP-expanded autolo-
gous or allogeneic antigen-specific T-cells and mock-treated mice was evalu-
ated by a linear mixed-effect model with time, group, and the interaction of 
time and group as predictors.
CONFlICT OF INTeReST
The authors declare no conflict of interest.
ACKNOWleDGMeNTS
R.K. and M.J.S. supported by a National Health and Medical Research Council (NH&MRC) 
Senior Principal Research Fellowship.
ReFeReNCeS
 1. Fishman, JA and Issa, NC (2010). Infection in organ transplantation: risk factors and 
evolving patterns of infection. Infect Dis Clin North Am 24: 273–283.
 2. Gratwohl, A, Brand, R, Frassoni, F, Rocha, V, Niederwieser, D, Reusser, P et al.; Acute and 
Chronic Leukemia Working Parties; Infectious Diseases Working Party of the European 
Group for Blood and Marrow Transplantation. (2005). Cause of death after allogeneic 
haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis 
of lethal infectious complications and changes over calendar time. Bone Marrow 
Transplant 36: 757–769.
 3. Green, M (2013). Introduction: Infections in solid organ transplantation. Am J Transplant 
13 Suppl 4: 3–8.
 4. Humar, A, Kumar, D, Preiksaitis, J, Boivin, G, Siegal, D, Fenton, J et al. (2005). A trial of 
valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. 
Am J Transplant 5: 1462–1468.
 5. Humar, A, Lebranchu, Y, Vincenti, F, Blumberg, EA, Punch, JD, Limaye, AP et al. (2010). The 
efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk 
kidney transplant recipients. Am J Transplant 10: 1228–1237.
 6. Humar, A, Limaye, AP, Blumberg, EA, Hauser, IA, Vincenti, F, Jardine, AG et al. (2010). 
Extended valganciclovir prophylaxis in D+/R− kidney transplant recipients is associated 
with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT 
study. Transplant 90: 1427–1431.
 7. Biron, KK (2006). Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71: 154–163.
 8. Boeckh, M (1999). Current antiviral strategies for controlling cytomegalovirus in 
hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis 
1: 165–178.
 9. Boeckh, M, Zaia, JA, Jung, D, Skettino, S, Chauncey, TR and Bowden, RA (1998). A study 
of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV 
prophylaxis in marrow transplantation. Biol Blood Marrow Transplant 4: 13–19.
 10. Hill, GR, Tey, SK, Beagley, L, Crough, T, Morton, JA, Clouston, AD et al. (2010). Successful 
immunotherapy of HCMV disease using virus-specific T cells expanded from an 
allogeneic stem cell transplant recipient. Am J Transplant 10: 173–179.
 11. Holmes-Liew, CL, Holmes, M, Beagley, L, Hopkins, P, Chambers, D, Smith, C et al. (2015). 
Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung 
transplantation. Clin Transl Immunology 4: e35.
 12. Khanna, R and Smith, C (2013). Cellular immune therapy for viral infections in transplant 
patients. Indian J Med Res 138: 796–807.
 13. Heslop, HE and Leen, AM (2013). T-cell therapy for viral infections. Hematology Am Soc 
Hematol Educ Program 2013: 342–347.
 14. Kaloyannidis, P, Leen, AM and Papadopoulou, A (2012). T-cell therapy: a powerful 
tool for the management of viral infections and relapse post hematopoietic stem cell 
transplantation. Expert Rev Hematol 5: 471–473.
 15. Tzannou, I and Leen, AM (2015). Preventing stem cell transplantation-associated viral 
infections using T-cell therapy. Immunotherapy 7: 793–810.
 16. Leen, AM, Bollard, CM, Mendizabal, AM, Shpall, EJ, Szabolcs, P, Antin, JH et al. (2013). 
Multicenter study of banked third-party virus-specific T cells to treat severe viral 
infections after hematopoietic stem cell transplantation. Blood 121: 5113–5123.
 17. Leen, AM, Myers, GD, Sili, U, Huls, MH, Weiss, H, Leung, KS et al. (2006). Monoculture-
derived T lymphocytes specific for multiple viruses expand and produce clinically 
relevant effects in immunocompromised individuals. Nat Med 12: 1160–1166.
 18. Melenhorst, JJ, Castillo, P, Hanley, PJ, Keller, MD, Krance, RA, Margolin, J et al. (2015). 
Graft versus leukemia response without graft-versus-host disease elicited by adoptively 
transferred multivirus-specific T-cells. Mol Ther 23: 179–183.
 19. Gerdemann, U, Keirnan, JM, Katari, UL, Yanagisawa, R, Christin, AS, Huye, LE et al. (2012). 
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and 
treatment of viral infections. Mol Ther 20: 1622–1632.
 20. Gerdemann, U, Vera, JF, Rooney, CM and Leen AM. (2011). Generation of multivirus-
specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell 
transplant. JoVE (51). pii: 2736. doi: 10.3791/2736.
 21. Smith, C, Økern, G, Rehan, S, Beagley, L, Lee, SK, Aarvak, T et al. (2015). Ex vivo expansion 
of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune 
Cell Serum Replacement. Clin Transl Immunology 4: e31.
 22. Bollard, CM, Gottschalk, S, Torrano, V, Diouf, O, Ku, S, Hazrat, Y et al. (2014). Sustained 
complete responses in patients with lymphoma receiving autologous cytotoxic T 
lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32: 
798–808.
 23. Bollard, CM, Rooney, CM and Heslop, HE (2012). T-cell therapy in the treatment of post-
transplant lymphoproliferative disease. Nat Rev Clin Oncol 9: 510–519.
 24. Fuji, S, Kapp, M, Grigoleit, GU and Einsele, H (2011). Adoptive immunotherapy with virus-
specific T cells. Best Pract Res Clin Haematol 24: 413–419.
 25. Fernández-Ruiz, M, Kumar, D and Humar, A (2014). Clinical immune-monitoring 
strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunol 
3: e12.
 26. Westervelt, JD, Alexander, BD, Costa, SF, Miller, SE, Howell, DN and Smith, SR (2013). 
Detection of BK polyomavirus after kidney transplantation: a comparison of urine 
electron microscopy with plasma polymerase chain reaction. Clin Transplant 27: E42–
E48.
 27. Ljungman, P, Hakki, M and Boeckh, M (2011). Cytomegalovirus in hematopoietic stem 
cell transplant recipients. Hematol Oncol Clin North Am 25: 151–169.
 28. Gerna,  G, Lilleri,  D, Furione,  M and Baldanti,  F (2011). Management of human 
cytomegalovirus infection in transplantation: validation of virologic cut-offs for 
preemptive therapy and immunological cut-offs for protection. New Microbiol 34: 229–
254.
 29. Gerdemann, U, Katari, UL, Papadopoulou, A, Keirnan, JM, Craddock, JA, Liu, H et al. (2013). 
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for 
9Preclinical assessment of multivirus immunotherapy
V Dasari et al.
Molecular Therapy — Methods & Clinical Development (2016) 16058Official journal of the American Society of Gene & Cell Therapy
adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. 
Mol Ther 21: 2113–2121.
 30. Papadopoulou, A, Gerdemann, U, Katari, UL, Tzannou, I, Liu, H, Martinez, C et al. (2014). 
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 
infections after HSCT. Sci Transl Med 6: 242ra83.
 31. Krause, PR, Bialek, SR, Boppana, SB, Griffiths, PD, Laughlin, CA, Ljungman, P et al. (2013). 
Priorities for CMV vaccine development. Vaccine 32: 4–10.
 32. Schleiss, MR (2009). VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential 
protection against CMV disease and infection. Curr Opin Mol Ther 11: 572–578.
 33. Wang, Z, Zhou, W, Srivastava, T, La Rosa, C, Mandarino, A, Forman, SJ et al. (2008). A fusion 
protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA 
vaccine vector. Virol 377: 379–390.
 34. Zhong, J and Khanna, R (2007). Vaccine strategies against human cytomegalovirus 
infection. Expert Rev Anti Infect Ther 5: 449–459.
 35. Elkington, R, Walker, S, Crough, T, Menzies, M, Tellam, J, Bharadwaj, M et al. (2003). Ex 
vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and 
multispecific reactivities in healthy virus carriers. J Virol 77: 5226–5240.
 36. Gandhi, MK and Khanna, R (2004). Human cytomegalovirus: clinical aspects, immune 
regulation, and emerging treatments. Lancet Infect Dis 4: 725–738.
 37. Hislop, AD, Taylor, GS, Sauce, D and Rickinson, AB (2007). Cellular responses to viral 
infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587–617.
 38. Leen, AM, Christin, A, Khalil, M, Weiss, H, Gee, AP, Brenner, MK et al. (2008). Identification 
of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 
82: 546–554.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or other 
third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission from the license holder to 
reproduce the material. To view a copy of this license, visit http://creativecommons.org/
licenses/by-nc-nd/4.0/
© The Author(s) (2016)
